Suppr超能文献

脱氧皮质酮醋酸盐-盐性高血压大鼠中的血管激肽释放酶

Vascular kallikrein in deoxycorticosterone acetate-salt hypertensive rats.

作者信息

Nolly H, Carretero O A, Lama M C, Miatello R, Scicli A G

机构信息

Argentine Council of Research (CONICET), School of Medicine, UNC, Mendoza.

出版信息

Hypertension. 1994 Jan;23(1 Suppl):I185-8. doi: 10.1161/01.hyp.23.1_suppl.i185.

Abstract

We determined the status of vascular kallikrein in rats with severe hypertension caused by treatment with deoxycorticosterone acetate (DOCA) and drinking of 1% NaCl for 6 weeks. We assayed active and total kininogenase (kallikrein) activity in the perfusate and in arterial and venous tissue. DOCA-salt rats had higher systolic blood pressure at 6 weeks (214 +/- 5 mm Hg) than rats drinking tap water (135 +/- 4 mm Hg) or saline (145 +/- 8 mm Hg). Kininogenase in the perfusate (nanograms bradykinin per minute per kilogram body weight) increased significantly at 2 weeks, from 5.8 +/- 2.1 to 8.9 +/- 1.4 for active kallikrein and from 28.7 +/- 0.4 to 48.7 +/- 2.9 for total kallikrein. Total kallikrein returned to control values at 4 weeks, whereas it was significantly reduced at 6 weeks (20.9 +/- 0.7). Active kallikrein was significantly depressed at 4 and 6 weeks (1.08 +/- 0.1 and 0.85 +/- 0.1, respectively [P < .05]). Active kallikrein in arterial tissue (picograms bradykinin per milligram per minute) showed a small but significant increase at 2 weeks, from 156 +/- 7 to 201 +/- 10 (P < .05), finally decreasing significantly by 6 weeks to 64 +/- 3; however, total kallikrein showed a significant decrease only at 6 weeks, from 844 +/- 17 to 427 +/- 27. Both active and total kallikrein in the veins were higher than control values at 2 weeks, changing from 437 +/- 7 to 541 +/- 19 and from 1619 +/- 17 to 2062 +/- 86, respectively. Venous kallikrein remained elevated until the end of the experiment.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

我们测定了用醋酸脱氧皮质酮(DOCA)处理并饮用1%氯化钠溶液6周所致重度高血压大鼠的血管激肽释放酶状态。我们检测了灌流液以及动脉和静脉组织中的活性激肽原酶(激肽释放酶)和总激肽原酶活性。DOCA-盐处理的大鼠在6周时收缩压(214±5 mmHg)高于饮用自来水的大鼠(135±4 mmHg)或饮用生理盐水的大鼠(145±8 mmHg)。灌流液中的激肽原酶(每千克体重每分钟纳克缓激肽)在2周时显著增加,活性激肽释放酶从5.8±2.1增至8.9±1.4,总激肽释放酶从28.7±0.4增至48.7±2.9。总激肽释放酶在4周时恢复至对照值,而在6周时显著降低(20.9±0.7)。活性激肽释放酶在4周和6周时显著降低(分别为1.08±0.1和0.85±0.1 [P <.05])。动脉组织中的活性激肽释放酶(每毫克每分钟皮克缓激肽)在2周时出现小幅但显著的增加,从156±7增至201±10(P <.05),最终在6周时显著降至64±3;然而,总激肽释放酶仅在6周时显著降低,从844±17降至427±27。静脉中的活性和总激肽释放酶在2周时均高于对照值,分别从437±7变为541±19以及从1619±17变为2062±86。静脉激肽释放酶在实验结束前一直保持升高。(摘要截断于250字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验